Summaries are drawn from public sources and link to them. HSH does not give a risk rating: read the summary and sources and reach your own view. Unproven allegations are labelled as such. Suppliers can submit a response, which is shown alongside.
Latest full-year results from official filings.
Parent Fujifilm Holdings (4901.T) group FY2025 revenue ¥3.36tn (+5.0%); operating margin 10.4%; net income ¥276.7bn.
Group figures; Healthcare is one of several segments.
Credible news about incidents, disputes, legal action or restructuring in the last 24 months.
No adverse media involving Fujifilm Healthcare found in HSH's search of the last 24 months.
Data breaches, cyber incidents, regulator action and assurance status.
Aug 2025: CISA published an advisory on a vulnerability in Fujifilm's Synapse Mobility image viewer that could allow access beyond role-based controls; Fujifilm released fixes (version 8.2 and patches) and workarounds. NHS DSPT status not yet checked.
Recalls, safety notices, regulator action and clinical safety concerns.
Jul 2026: Fujifilm Healthcare Americas began a US Class 2 recall of Synapse PACS v7.4.310 because a software issue could make ruler measurements inaccurate (6 units).
Contract delivery, go-lives, terminations and disputes.
No notable contract disputes, terminations or troubled implementations involving Fujifilm Healthcare found in HSH's search of the last 24 months.